Mexico Chronic Cough Therapeutics Market Analysis

Mexico Chronic Cough Therapeutics Market Executive Summary

Mexico's Chronic Cough Therapeutics Market was valued at $95 Mn in 2022 and is estimated to reach $179 Mn in 2030, exhibiting a CAGR of 8.35% during the forecast period.

Chronic cough is a persistent cough that lasts for an extended period, typically lasting more than eight weeks. Unlike acute coughs, often associated with infections or other short-term conditions, chronic cough can be a symptom of an underlying, more persistent health issue. Common causes of chronic cough include respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), gastroesophageal reflux disease (GERD), postnasal drip, and certain medications. Identifying and addressing the underlying cause of chronic cough through a thorough medical evaluation is important, as treating the root issue is crucial for effective management. Chronic cough can significantly impact an individual's quality of life and may require a multidisciplinary approach involving healthcare professionals such as pulmonologists, gastroenterologists, or ear, nose, and throat (ENT) specialists for comprehensive care.

In 2023, Mexico encountered a significant health issue as 40% of individuals with post-acute sequelae after SARS-CoV-2 infection (PASC) experienced chronic cough. Among adults aged 20 and above, 12.44% suffered from persistent symptoms, particularly chronic cough, following SARS-CoV-2 infection. PASC was identified as the primary cause of chronic cough, indicating the long-term effects of SARS-CoV-2. Factors such as SARS-CoV-2 reinfections, depressive symptoms, and living in regions with high social lag were linked to higher PASC prevalence. This complex relationship highlights the necessity for specific public health measures to tackle the enduring impact of SARS-CoV-2 and the various factors influencing chronic cough prevalence in the population.

Trevi Therapeutics is conducting a Phase IIa RIVER clinical trial for its investigational therapeutic, Haduvio, to treat refractory chronic cough. The trial aims to evaluate the safety and efficacy of Haduvio in reducing persistent coughing that does not respond to standard treatments. Haduvio has a dual mechanism of action, acting as both an agonist to the kappa opioid receptor and as an antagonist to the body's mu-opioid receptor, and has the potential to work regardless of whether the initial cough trigger originates in the lung or in the central nervous system. The initiative underscores the commitment to advancing respiratory health research and addressing unmet needs in the field, potentially providing a novel and effective therapeutic option for individuals struggling with refractory chronic cough.

Market Dynamics

Market Growth Drivers

Rising prevalence of chronic cough: In Mexico, chronic cough is a prevalent condition, impacting approximately 10% of the population. The likelihood of this condition is anticipated to grow, attributed to factors like rising levels of air pollution, smoking habits, and an aging population.

Expanding access to healthcare: The Mexican authorities are broadening healthcare accessibility, facilitating improved diagnosis and treatment for chronic cough. This effort encompasses initiatives like Seguro Popular, extending health insurance coverage to individuals with low incomes.

Changing Lifestyles and Environmental Factors: Changes in lifestyle patterns and exposure to environmental pollutants can contribute to the increased occurrence of chronic cough. As these factors evolve, the demand for therapeutics addressing lifestyle-related respiratory issues is likely to grow.

Market Restraints

Limited Awareness and Diagnosis: A significant restraint lies in the limited awareness about chronic cough and its potential underlying causes among both the general public and healthcare professionals. This can result in delayed diagnosis and treatment initiation, hindering market growth.

Affordability and Accessibility Issues: Economic disparities and healthcare affordability concerns in Mexico may limit access to chronic cough therapeutics for certain segments of the population. Affordability issues can be a significant restraint, particularly in regions with lower socioeconomic status.

Regulatory Challenges: The chronic cough therapeutics industry in Mexico presents pharmaceutical companies and healthcare providers with regulatory obstacles due to intricate regulatory frameworks and approval processes. The introduction of novel drugs and treatments may be slowed down by regulatory obstacles, which might hinder market expansion.

Healthcare Policies and Regulatory Landscape

In Mexico, the Federal Committee for Protection against Sanitary Risk (COFEPRIS), a division under the Ministry of Health, plays a significant role in overseeing healthcare policies and exercising regulatory authority over therapeutic drugs. COFEPRIS collaborates with the Ministry of Health to ensure the effectiveness, safety, and quality of medications. The National Cancer Institute (INCan) serves as a key reference organization for cancer care, while the National Institute of Public Health (INSP) contributes to the scientific foundation guiding healthcare decisions. The Mexican Social Security Institute (IMSS) influences drug accessibility and regulatory guidelines for insured individuals, and the General Health Council offers counsel on health-related issues. Furthermore, the National Commission for Protection against Health Risks (CONARIS) facilitates risk assessment and management.

Competitive Landscape

Key Players

• Cipla Inc.
• Reckitt Benckiser Group plc.
• Hikma Pharmaceuticals Plc
• Merck
• Novartis
• Bellus Health
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• Bayer